Avid Bioservices Inc (CDMO)

[biopharm]

Riddell me this: Why did MSK stop with Juno on this type of approach? Maybe Stanley just looking to pick up any cash he can for some patents that are out there. If you have what it takes, you stay quiet and maneuver to the front pole position and if you don't have what it takes, you chery pick some data that shows only the positive but I think genetically re-engineering cells is a damn bad idea

---------------------------------------------------

Stanley Riddell - patents:

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells.

http://patents.justia.com/inventor/stanley-r-riddell

...disclosures for Riddell lead to cell medica / Juno Therapeutics
http://www.aacr.org/EducationTraining/Shared%20Documents/Continuing%20Medical%20Education/2015%20Conferences/%285%29%20AM15/AM15%20All%20Disclosures%204.15.15.pdf

-------------------------------------

Two deaths force MSK to hit the brakes on engineered T cell cancer study

April 6, 2014

..
..

Several days ago MSK updated a site on clinicaltrials.gov to note that it was halting recruitment for a small study using T cells reengineered with chimeric antigen receptors (CARs)

http://www.fiercebiotech.com/story/memorial-sloan-kettering-hits-brakes-engineered-t-cell-cancer-study/2014-04-06

See Timeline = Oct 1, 2014, notice Hal Barrons position and MSK drops the idea of genetically re-engineering cells..etc..... heck, re-engineering / genetically modifying T-cells has already proven to bring increased risk to the patient.... and MSK stops with that approach with Juno and picks up Peregrines platform re: PS Targeting... for a very safe reason!

http://investorshub.advfn.com/boards/replies.aspx?msg=115979520